Current Issues in Chronic Myeloid Leukemia: Monitoring, Resistance, and Functional Cure

被引:0
作者
Cortes, Jorge [1 ]
Goldman, John M. [2 ]
Hughes, Timothy [3 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ London Imperial Coll Sci Technol & Med, Div Invest Sci, London, England
[3] Ctr Canc Biol, Dept Med, Dept Hematol, Adelaide, SA, Australia
来源
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2012年 / 10卷
关键词
CHRONIC MYELOGENOUS LEUKEMIA; COMPLETE CYTOGENETIC RESPONSE; ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; EARLY MOLECULAR RESPONSE; KINASE DOMAIN MUTATIONS; BCR-ABL; IMATINIB MESYLATE; SUBOPTIMAL RESPONSE; EUROPEAN LEUKEMIANET;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite the success with tyrosine kinase inhibitors (TKIs) in most patients with chronic myelogenous leukemia (CML), some patients still experience resistance or intolerance and need alternative therapies. Monitoring response to TKI therapy is a critical component of managing CML, and molecular response seems to be the most important milestone for predicting long-term outcomes. How best to assess response, including how to define treatment failure, and how monitoring should be conducted remain controversial. Strategies for overcoming imatinib resistance include increasing the imatinib dose or switching to a second-generation TKI. Another approach is to use higher doses of imatinib or second-generation TKIs up front to increase the rate of earlier responses, with the hope that this will translate into a reduced risk of resistance. Several investigational therapies are also being evaluated as a means of overcoming TKI resistance, including ponatinib (AP24534), omacetaxine, and bosutinib (SKI-606). Allogeneic hematopoietic stem cell transplantation has also shown efficacy in patients with imatinib-resistant disease. Alternatives to long-term TKI therapy that are currently being explored include discontinuation of treatment and eradication of minimal residual disease with investigational treatment regimens, such as those involving interferon, hydroxychloroquine, BCL6 inhibitors, and the smoothened antagonists LDF225 and BMS-833923. (JNCCN 2012;10[Suppl 3]:S1-513)
引用
收藏
页码:S1 / S13
页数:13
相关论文
共 50 条
  • [41] Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
    Tolomeo, Manlio
    Dieli, Francesco
    Gebbia, Nicola
    Simoni, Daniele
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (08) : 853 - 863
  • [42] Why Doesn't Imatinib Cure Chronic Myeloid Leukemia?
    Redner, Robert L.
    ONCOLOGIST, 2010, 15 (02) : 182 - 186
  • [43] Managing imatinib resistance in chronic myeloid leukaemia
    Osborn, Michael
    Hughes, Timothy
    CURRENT OPINION IN HEMATOLOGY, 2010, 17 (02) : 97 - 103
  • [44] Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan
    Yoshida, Chikashi
    Fletcher, Linda
    Ohashi, Kazuteru
    Wakita, Hisashi
    Kumagai, Takashi
    Shiseki, Masayuki
    Matsuei, Kousei
    Inokuchi, Koiti
    Hatta, Yoshihiro
    Shirasugi, Yukari
    Yamaguchi, Toshikazu
    Sakamoto, Junichi
    Branford, Susan
    Sakamaki, Hisashi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2012, 17 (06) : 584 - 589
  • [45] Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring
    Jabbour, Elias
    Kantarjian, Hagop
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (11) : 2191 - 2212
  • [46] Treatment and molecular monitoring update in chronic myeloid leukemia management
    Sorel, Nathalie
    Cayssials, Emilie
    Brizard, Francoise
    Chomel, Jean-Claude
    ANNALES DE BIOLOGIE CLINIQUE, 2017, 75 (02) : 129 - 145
  • [47] Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
    Jabbour, Elias
    Kantarjian, Hagop
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (03) : 442 - 459
  • [48] Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management
    Jabbour, Elias
    Kantarjian, Hagop
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (05) : 547 - 556
  • [49] Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
    Jabbour, Elias
    Kantarjian, Hagop
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (06) : 691 - 709
  • [50] Chronic myeloid leukemia: 2012 Update on diagnosis, monitoring, and management
    Jabbour, Elias
    Kantarjian, Hagop
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (11) : 1038 - 1045